26 Nov 2024 by admin in UncategorizedComments Oricell Therapeutics Receives China NMPA IND Clearance for MSLN/Claudin 18.2 Dual CAR-T Therapy for Solid Tumors
26 Nov 2024 by admin in UncategorizedComments Adcentrx Therapeutics Announces FDA Clearance of Investigational New Drug Application for ADRX-0405, a Potential First-in-Class ADC Targeting STEAP1 for the Treatment of Advanced Solid Tumors
20 Nov 2024 by admin in UncategorizedComments Avenzo Therapeutics Announces Appointment of Patrick Machado, J.D. to Board of Directors as Independent Director
19 Nov 2024 by admin in UncategorizedComments Preclinical Data Demonstrates Anti-Siglec-15 Treatment Enhanced Generation of Quality Bone with Better Mechanical Properties in Mice with Moderate-to-Severe Osteogenesis Imperfecta
18 Nov 2024 by admin in UncategorizedComments Adicet Bio Announces First Lupus Nephritis Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases
12 Nov 2024 by admin in UncategorizedComments Zenas BioPharma Completes Targeted Enrolment of the Phase 3 INDIGO Trial of Obexelimab in Imunoglobulin G4-Related Disease (IgG4-RD) in Immunoglobulin G4-Related Disease (IgG4-RD)
12 Nov 2024 by admin in UncategorizedComments Tempest Receives FDA Study May Proceed for Pivotal Phase 3 Trial of Amezalpat Combination Therapy for the Treatment of First-Line Hepatocellular Carcinoma
10 Nov 2024 by admin in UncategorizedComments Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial
23 Oct 2024 by admin in UncategorizedComments Interius BioTherapeutics Doses First Patient with in vivo Chimeric Antigen Receptor (CAR) Gene Therapy for B-cell Malignancies
16 Oct 2024 by admin in UncategorizedComments Adicet Bio Announces FDA Clearance of IND Amendment to Evaluate ADI-001 in Idiopathic Inflammatory Myopathy and Stiff Person Syndrome
30 Sep 2024 by admin in UncategorizedComments Adicet Opens Enrollment for ADI-001 Phase 1 Clinical Trial in Autoimmune Diseases
18 Sep 2024 by admin in UncategorizedComments Tempest Further Strengthens Leadership Team with Appointment of Sheldon Mullins as Vice President, Regulatory Affairs
12 Sep 2024 by admin in UncategorizedComments Zenas BioPharma Announces Pricing of Upsized Initial Public Offering
10 Sep 2024 by admin in UncategorizedComments Adcentrx Therapeutics Announces Formation of Scientific Advisory Board
03 Sep 2024 by admin in UncategorizedComments Avenzo Therapeutics Announces Clinical Study Collaboration with Gilead Sciences to Evaluate AVZO-021 and Trodelvy® in HR+/HER2- Metastatic Breast Cancer
20 Aug 2024 by admin in UncategorizedComments Renowned Myeloma Experts Dr. Kenneth C. Anderson and Dr. Shaji Kumar join Scientific Advisory Board of Oricell Therapeutics
19 Aug 2024 by admin in UncategorizedComments Adicet Bio Appoints Lloyd Klickstein, M.D., Ph.D. to the Board of Directors
08 Aug 2024 by admin in UncategorizedComments Adicet Bio Receives FDA Fast Track Designation for ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma
15 Jul 2024 by admin in UncategorizedComments Oricell Therapeutics’ GPRC5D-Targeted CAR-T Therapy, OriCAR-017, Receives FDA Fast Track Designation for Relapsed/Refractory Multiple Myeloma
15 Jul 2024 by admin in UncategorizedComments Eluminex Biosciences Announces First Patient Dosed in the Phase 1b LOTUS Trial of the Novel Trispecific Fusion Antibody EB-105 in Diabetic Macular Edema (DME)
09 Jul 2024 by admin in UncategorizedComments nterius BioTherapeutics Receives HREC Approval and CTN Clearance from the TGA to Commence a Phase 1 Clinical Trial for Its First-in-Class In Vivo CAR Therapeutic for B Cell Malignancies
01 Jul 2024 by admin in UncategorizedComments Zenas BioPharma Appoints Orlando Oliveira as Chief Commercial Officer July 1, 2024
25 Jun 2024 by admin in UncategorizedComments Alebund’s Innovative Investigational Drug AP306 Receives NMPA’s Breakthrough Therapy Designation (BTD) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease (CKD)
15 May 2024 by admin in UncategorizedComments Sail Biomedicines Appoints Clinical and Scientific Leader Dr. Wendy Chung to Its Board
15 May 2024 by admin in UncategorizedComments Arcellx and Kite Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
13 May 2024 by admin in UncategorizedComments RareStone Group Announces Appointment of Andy Zhang and Hardy Huan as Co-CEOs
07 May 2024 by admin in UncategorizedComments Zenas BioPharma Announces Upsized $200 Million Series C Financing to Advance Mid- and Late-Stage Immunology-Focused Clinical Development Programs
06 May 2024 by admin in UncategorizedComments Adcentrx Therapeutics Announces China NMPA Grants IND Clearance for ADRX-0706, a Novel Nectin-4 ADC for the Treatment of Advanced Solid Tumors
30 Apr 2024 by admin in UncategorizedComments Eluminex Biosciences Announces FDA Acceptance of Investigational New Drug (IND) Application for EB-105 – A Novel Trispecific Fusion Antibody for Diabetic Macular Edema (DME) – and Upcoming Scientific Presentations
26 Apr 2024 by admin in UncategorizedComments Crescendo Biologics announces that Zai Lab has initiated a global Phase 2 clinical trial evaluating ZL-1102 (Humabody®, CB001) as a topical treatment for psoriasis
08 Apr 2024 by admin in UncategorizedComments Adcentrx Therapeutics Appoints Meng Jiang as Chief Financial Officer
29 Mar 2024 by admin in UncategorizedComments Alebund’s Innovative Investigational Drug AP303 Receives FDA Orphan Drug Designation (ODD) for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
26 Mar 2024 by admin in UncategorizedComments Avenzo Therapeutics Announces $150 Million Oversubscribed Financing To Advance Emerging Oncology Pipeline
06 Mar 2024 by admin in UncategorizedComments Zenas BioPharma Appoints Patricia Allen to its Board of Directors
07 Feb 2024 by admin in UncategorizedComments Sail Biomedicines Appoints Kerry Benenato, Ph.D., as Chief Platform Officer
29 Jan 2024 by admin in UncategorizedComments Oricell Announces FDA Clearance of IND Application for OriCAR- 017, a novel GPRC5D Targeted CAR-T Cell Therapy Utilizing the Company’s Proprietary Platform, for the Treatment of Relapsed/Refractory Multiple Myeloma
25 Jan 2024 by admin in UncategorizedComments Adicet Bio, Inc. Announces Closing of $98 Million Public Follow-On Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
18 Jan 2024 by admin in UncategorizedComments NextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway Disorders
15 Jan 2024 by admin in UncategorizedComments Sail Biomedicines Provides Update on Research with Cystic Fibrosis Foundation and Pioneering Medicines
